Imagen de Portada
Código QR

Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.

On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug u...

Descripción completa

Publicado en:MMWR: Morbidity & Mortality Weekly Report Vol. 62; no. 23; pp. 463 - 466
Formato: Journal Article
Publicado: Centers for Disease Control & Prevention (CDC) 6/14/2013
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104178497&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104178497
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01492195
        MMW
      jtl: MMWR: Morbidity & Mortality Weekly Report
      issn: 01492195
      maglogo: N
    pubinfo:
      dt: 6/14/2013
      vid: 62
      iid: 23
      pid: 1493
      pub: Centers for Disease Control & Prevention (CDC)
      place: Atlanta, Georgia
    artinfo:
      ui:
        104178497
        NLM23760186
        2012152909
        NLM23760186
        104178497
      ppf: 463
      ppct: 3
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
      aug:
      sug:
        subj:
          Purines Analogs and Derivatives
          Anti-HIV Agents Therapeutic Use
          Deoxycytidine
          HIV Infections Prevention and Control
          Practice Guidelines
          Substance Abuse, Intravenous
          Purines Therapeutic Use
          Centers for Disease Control and Prevention (U.S.)
          Deoxycytidine Therapeutic Use
          Female
          HIV Infections Epidemiology
          Heterosexuality
          Homosexuality
          Male
          Clinical Trials
          Risk Assessment
          United States
          Female
          Male
      ab: On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N